Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Non-Current Liabilities: 2021

Historic Total Non-Current Liabilities for ARS Pharmaceuticals (SPRY) over the last 1 years, with Dec 2021 value amounting to $16.6 million.

  • ARS Pharmaceuticals' Total Non-Current Liabilities was N/A to $221.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.4 million, marking a year-over-year change of. This contributed to the annual value of $16.6 million for FY2021, which is N/A change from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Total Non-Current Liabilities of $16.6 million as of FY2021.
  • Over the past 5 years, ARS Pharmaceuticals' Total Non-Current Liabilities peaked at $16.6 million during FY2021, and registered a low of $16.6 million during FY2021.
  • Moreover, its 1-year median value for Total Non-Current Liabilities was $16.6 million (2021), whereas its average is $16.6 million.